Last reviewed · How we verify

Investigational COVID-19 Vaccine

BioNTech · FDA-approved active Biologic Quality 40/100

Investigational COVID-19 Vaccine is a Not specified Biologic drug developed by BioNTech. It is currently FDA-approved for Prevention of COVID-19 in individuals 5 years of age and older, Prevention of COVID-19 in individuals 6 months through 4 years of age, Prevention of COVID-19 in individuals 12 years of age and older.

BioNTech's investigational COVID-19 vaccine is currently marketed for the prevention of COVID-19 in individuals aged 5 years and older. The vaccine holds a strong market position with key patent protection until 2028, providing a significant barrier to entry for generic competitors. However, the vaccine faces competition from Invivyd’s pemivibart and adintrevimab, which share similar antibody backbones and have demonstrated robust safety and efficacy in clinical trials.

At a glance

Generic nameInvestigational COVID-19 Vaccine
SponsorBioNTech
Drug classNot specified
TargetNot specified
ModalityBiologic
Therapeutic areaInfectious Disease
PhaseFDA-approved

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Investigational COVID-19 Vaccine

What is Investigational COVID-19 Vaccine?

Investigational COVID-19 Vaccine is a Not specified drug developed by BioNTech, indicated for Prevention of COVID-19 in individuals 5 years of age and older, Prevention of COVID-19 in individuals 6 months through 4 years of age, Prevention of COVID-19 in individuals 12 years of age and older.

What is Investigational COVID-19 Vaccine used for?

Investigational COVID-19 Vaccine is indicated for Prevention of COVID-19 in individuals 5 years of age and older, Prevention of COVID-19 in individuals 6 months through 4 years of age, Prevention of COVID-19 in individuals 12 years of age and older, Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions, Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions.

Who makes Investigational COVID-19 Vaccine?

Investigational COVID-19 Vaccine is developed and marketed by BioNTech (see full BioNTech pipeline at /company/biontech).

What drug class is Investigational COVID-19 Vaccine in?

Investigational COVID-19 Vaccine belongs to the Not specified class. See all Not specified drugs at /class/not-specified.

What development phase is Investigational COVID-19 Vaccine in?

Investigational COVID-19 Vaccine is FDA-approved (marketed).

What are the side effects of Investigational COVID-19 Vaccine?

Common side effects of Investigational COVID-19 Vaccine include Headache, Injection site pain, Fatigue, Myalgia, Chills, Pyrexia.

What does Investigational COVID-19 Vaccine target?

Investigational COVID-19 Vaccine targets Not specified and is a Not specified.

Related